Novo Nordisk’s new ultrafast-acting insulin got sidelined by the FDA last year, but the drugmaker is launching it in markets in Europe and elsewhere.
Following a January approval in the EU, Novo introduced fast-acting insulin aspart, Fiasp, in the U.K. this week. The rollout followed earlier pushes in Germany and Canada for the “ultra-fast rapid-acting insulin” that trials show more closely mimics the body’s natural insulin production.
Novo has launches throughout Europe planned for the first half of this year, the company said in an earlier statement about the EU approval. It’s filed for approval in several other countries including the U.S.
Novo’s restructuring hit its R&D and commercial operations as the company shifted its focus to innovative new products.
With Fiasp, it’s offering a product that brings “incremental benefits … comparable to those observed for the last generation of mealtime insulins when introduced more than a decade ago,” Chief Science Officer Mads Krogsgaard Thomsen said in a release.